Multi-drug-resistant tuberculosis classification: Difference between revisions
No edit summary |
m (Changes made per Mahshid's request) |
||
(6 intermediate revisions by 2 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Multi-drug-resistant tuberculosis}} | {{Multi-drug-resistant tuberculosis}} | ||
{{CMG}} ; {{AE}} {{Ammu}} | {{CMG}} ; {{AE}} {{Ammu}} | ||
==Overview== | ==Overview== | ||
Classification of drug resistant tuberculosis is based on drug susceptibility , pathophysiology, clinical classification and molecular classification. According to drug susceptibility it is classified as monoresistance, poly resistance, multidrug resistance, extensive drug resistance and [[rifampicin]] resistance. Clinically it is classified as acquired and [[primary resistance]]. The [[restriction fragment length polymorphism]] helps for molecular classification into unique and cluster type. | |||
==Classification== | ==Classification== | ||
Based on the drug susceptibility testing of cinical isolates confirmed to be Mycobacterium tuberculosis, | Based on the drug susceptibility testing of cinical isolates confirmed to be [[Mycobacterium tuberculosis]], | ||
the strains are classified as follows. <ref name=WHO>{{cite web | title =Drug resistance Classification| url =http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf }}</ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px; width: 700px" align=center | ||
|valign=top| | |valign=top| | ||
|+ | |+ | ||
Line 15: | Line 18: | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to any one of the first line anti tubercular drugs | | style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to any one of the first line anti tubercular drugs | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Polydrug resistance | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Polydrug resistance]] | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to more than one first line anti tubercular drugs. (Other than both rifampicin and isoniazid) | | style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to more than one first line anti tubercular drugs. (Other than both [[rifampicin]] and [[isoniazid]]) | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Multidrug resistance | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Multidrug resistance | ||
| style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to both rifampicin and isoniazid | | style="padding: 5px 5px; background: #F5F5F5;" |Strain resistant to both [[rifampicin]] and [[isoniazid]] | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Extensive drug resistance | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Extensive drug resistance | ||
| style="padding: 5px 5px; background: #F5F5F5;" |In addition to the multi drug resistance, strain is resistant to any fluroquinolone and to atleast one of the three second line anti | | style="padding: 5px 5px; background: #F5F5F5;" |In addition to the multi drug resistance, strain is resistant to any [[fluroquinolone]] and to atleast one of the three second line injectable anti [[TB]] drugs like [[amikacin]], [[capreomycin]] and [[kanamycin]]. | ||
|- | |- | ||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |Rifampicin resistance | | style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" |[[Rifampicin]] resistance | ||
| style="padding: 5px 5px; background: #F5F5F5;" | Using genotypic or phenotypic method, strain has been detected to have resistance to rifampicin with or without resistance to other anti TB drugs. It can include monoresistance, multi drug resistance, poly drug resistance or extensive drug resistance. | | style="padding: 5px 5px; background: #F5F5F5;" | Using genotypic or phenotypic method, strain has been detected to have resistance to [[rifampicin]] with or without resistance to other anti [[TB]] drugs. It can include monoresistance, multi drug resistance, poly drug resistance or extensive drug resistance. | ||
|} | |} | ||
===Clinical classification=== | ===Clinical classification=== | ||
Clinically drug resistant tuberculosis can be classified into acquired drug resistance and primary drug resistance according to pathophysiology. | Clinically drug resistant tuberculosis can be classified into acquired drug resistance and primary drug resistance according to pathophysiology.<ref name="pmid10892760">{{cite journal| author=Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N et al.| title=Classification of drug-resistant tuberculosis in an epidemic area. | journal=Lancet | year= 2000 | volume= 356 | issue= 9223 | pages= 22-5 | pmid=10892760 | doi=10.1016/S0140-6736(00)02429-6 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10892760 }} </ref> | ||
====Acquired resistance==== | ====Acquired resistance==== | ||
Line 45: | Line 48: | ||
===Molecular classification=== | ===Molecular classification=== | ||
====Unique==== | ====Unique==== | ||
The restriction fragment length polymorphism helps in molecular classification of drug resistance into unique strains of drug resistance. | |||
====Cluster==== | ====Cluster==== | ||
==== | The restriction fragment length polymorphism helps in molecular classification of drug resistance into cluster of strains of drug resistance. | ||
====Classification based on pathogenesis==== | |||
Below is a table with the current classification system of [[tuberculosis]] ([[TB]]), based on its [[pathogenesis]]:<ref name=CDC>{{cite web | title = TB Classification | url = http://www.cdc.gov/tb/publications/slidesets/selfstudymodules/module1/classification.htm }}</ref> | |||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | |||
|valign=top| | |||
|+ | |||
! style="background: #4479BA; width: 50px;" | {{fontcolor|#FFF|Class}} | |||
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Type of Tuberculosis}} | |||
! style="background: #4479BA; width: 250px;" | {{fontcolor|#FFF|Description}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" | | |||
0 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
No [[TB]] exposure<br> | |||
Not infected | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
No history of [[TB]] exposure<br> | |||
Negative result to a [[TST]] or [[IGRA]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
1 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[TB]] exposure<br> | |||
No evidence of [[infection]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
History of [[TB]] exposure<br> | |||
Negative result to a [[TST]] (given at least 8-10 weeks after exposure) or [[IGRA]] | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
2 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[TB]] infection<br> | |||
No [[TB]] disease | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Positive result to a [[TST]] or [[IGRA]]<br> | |||
Negative smears and cultures (if done)<br> | |||
No clinical or [[x-ray]] evidence of active [[TB]] disease | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
3 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Clinically active [[TB]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Positive culture (if done) for ''[[M. tuberculosis]]''<br> | |||
Positive result to a [[TST]] or [[IGRA]], and clinical, bacteriological, or [[x-ray]] evidence of [[TB]] disease | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
4 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Previous [[TB]] disease (not clinically active) | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Medical history of [[TB]] disease<br> | |||
Abnormal but stable [[x-ray]] findings<br> | |||
Positive result to a [[TST]] or [[IGRA]]<br> | |||
Negative smears and cultures (if done)<br> | |||
No clinical or [[x-ray]] evidence of active [[TB]] disease | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;font-weight: bold" | | |||
5 | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
Suspected [[TB]] | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[Signs]] and [[symptoms]] of [[TB]] disease, but incomplete evaluation | |||
|- | |||
|} | |||
==References== | ==References== | ||
Line 57: | Line 127: | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Tuberculosis| ]] | [[Category:Tuberculosis| ]] | ||
Latest revision as of 18:06, 18 September 2017
Multi-drug-resistant tuberculosis Microchapters |
Differentiating Multi-drug-resistant tuberculosis from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Multi-drug-resistant tuberculosis classification On the Web |
American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis classification |
Multi-drug-resistant tuberculosis classification in the news |
Directions to Hospitals Treating Multi-drug-resistant tuberculosis |
Risk calculators and risk factors for Multi-drug-resistant tuberculosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Classification of drug resistant tuberculosis is based on drug susceptibility , pathophysiology, clinical classification and molecular classification. According to drug susceptibility it is classified as monoresistance, poly resistance, multidrug resistance, extensive drug resistance and rifampicin resistance. Clinically it is classified as acquired and primary resistance. The restriction fragment length polymorphism helps for molecular classification into unique and cluster type.
Classification
Based on the drug susceptibility testing of cinical isolates confirmed to be Mycobacterium tuberculosis, the strains are classified as follows. [1]
Classification | Description |
---|---|
Monoresistance | Strain resistant to any one of the first line anti tubercular drugs |
Polydrug resistance | Strain resistant to more than one first line anti tubercular drugs. (Other than both rifampicin and isoniazid) |
Multidrug resistance | Strain resistant to both rifampicin and isoniazid |
Extensive drug resistance | In addition to the multi drug resistance, strain is resistant to any fluroquinolone and to atleast one of the three second line injectable anti TB drugs like amikacin, capreomycin and kanamycin. |
Rifampicin resistance | Using genotypic or phenotypic method, strain has been detected to have resistance to rifampicin with or without resistance to other anti TB drugs. It can include monoresistance, multi drug resistance, poly drug resistance or extensive drug resistance. |
Clinical classification
Clinically drug resistant tuberculosis can be classified into acquired drug resistance and primary drug resistance according to pathophysiology.[2]
Acquired resistance
According to WHO , acquired resistance is defined as the isolation of drug resistant M. tuberculosis from a patient who has been treated for TB for one month or longer. Strains can acquire resistance against anti tubercular drugs in the following conditions.
- Inadequately treated by errors by caregivers in prescribing or administering drugs or supplying a poor quality drug
- Patients not completing the full course of treatment
- Patient receiving only partial treatment.
Such conditions can lead to the bacterial population to live for several months during the course of treatment thereby developing resistance against such drugs.
Primary resistance
WHO defines primary resistanc as the isolation of a drug resistant strain from a patient without a history of previous treatment. When a patient gets infected with strains already resistant to anti tubercular drugs it is called as primary resistance. It could be against one drug of 1st line anti tubercular drugs or many drugs in the first and second line of drugs.
Molecular classification
Unique
The restriction fragment length polymorphism helps in molecular classification of drug resistance into unique strains of drug resistance.
Cluster
The restriction fragment length polymorphism helps in molecular classification of drug resistance into cluster of strains of drug resistance.
Classification based on pathogenesis
Below is a table with the current classification system of tuberculosis (TB), based on its pathogenesis:[3]
Class | Type of Tuberculosis | Description |
---|---|---|
0 |
No TB exposure |
|
1 |
History of TB exposure | |
2 |
Positive result to a TST or IGRA | |
3 |
Clinically active TB |
Positive culture (if done) for M. tuberculosis |
4 |
Previous TB disease (not clinically active) |
Medical history of TB disease |
5 |
Suspected TB |
References
- ↑ "Drug resistance Classification" (PDF).
- ↑ Van Rie A, Warren R, Richardson M, Gie RP, Enarson DA, Beyers N; et al. (2000). "Classification of drug-resistant tuberculosis in an epidemic area". Lancet. 356 (9223): 22–5. doi:10.1016/S0140-6736(00)02429-6. PMID 10892760.
- ↑ "TB Classification".